PRESS RELEASE

04 April 2025 07:30:00 CEST

Ascelia Pharma Announces Acceptance of Study on Burden of Illness Real-World Data of Orviglance Target Patients for Presentation at the ISPOR 2025 Conference

Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that the abstract titled 'Burden of Illness in US Patients with Liver Cancer and Kidney Disease – A Real-World Claims Analysis' has been accepted for presentation at the Professional Society for Health Economics and Outcomes Research (ISPOR) Conference, taking place 13-16 May in Montreal, Canada.

Real-world data is increasingly important to decision makers as it provides insights and data on patient populations, clinical practice and drugs from sources other than prospective clinical trials.

"ISPOR is a key conference for payers, policy makers, healthcare providers, patient organizations and industry players. This abstract acceptance is an opportunity to share data on the patient vulnerability and unmet need for Orviglance® with these key stakeholders. The real-world data support the commercial potential for Orviglance and is valuable in the dialogue with potential commercialization partners," says Julie Waras Brogren, Deputy CEO of Ascelia Pharma.

The real-world data show that the target patient population for Orviglance, i.e. patients with liver cancer and kidney impairment, had more abdominal imaging procedures both in comparison to those without kidney impairment and to those with other cancers.

The data also show that target patients for Orviglance typically have several co-morbidities, such as diabetes and hypertension, and higher overall medical costs.

This real-world study used retrospective US patient claims datasets over 24 months, including Medicare data. The study compared demographics, imaging procedures, co-morbidities and use of healthcare resources for 230,000 cancer patients, of which 5% had liver cancer (primary or metastases) and of these 3,8% had severe kidney impairment, and 23.9% acute kidney injury during the 24-month period.

Ascelia Pharma expects to submit the New Drug Application (NDA) file for Orviglance to the US Food and Drug Administration (FDA) by mid-2025 to obtain regulatory approval.

About us

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance and Oncoral – in clinical development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit http://www.ascelia.com.

Contacts

Magnus Corfitzen, CEO
Email: moc@ascelia.com
Tel: +46 735 179 118

Julie Waras Brogren, Deputy CEO (Finance, Investor Relations & Commercial)
Email: jwb@ascelia.com
Tel: +46 735 179 116

This information was submitted for publication, through the agency of the contact persons set out above.

Attachments

Ascelia Pharma Announces Acceptance of Study on Burden of Illness Real-World Data of Orviglance Target Patients for Presentation at the ISPOR 2025 Conference